Adenosine Deaminase 2 (ADA2) deficiency presents a diagnostic conundrum, especially when it manifests with atypical features. While vasculitis is a well-recognized hallmark, this report highlights the importance of considering ADA2 deficiency in patients presenting with early-onset neutropenia and mixed inflammatory phenotypes. The diagnostic delay is often significant. The challenge lies in differentiating ADA2 deficiency from other causes of neutropenia and inflammatory disorders, which requires a high index of suspicion and appropriate genetic testing.
For clinicians, this means expanding our differential diagnosis in cases of unexplained neutropenia, particularly when accompanied by seemingly unrelated inflammatory symptoms. Early diagnosis is critical because targeted therapies, such as TNF inhibitors or hematopoietic stem cell transplantation, can dramatically alter the disease course.
Clinical Key Takeaways
lightbulb
- The PivotADA2 deficiency should be considered in the differential diagnosis of early-onset neutropenia, even in the absence of classic vasculitic features, which broadens the diagnostic criteria.
- The DataThe study highlights cases with overlapping clinical features, emphasizing that presentations can be heterogeneous and may delay diagnosis by months or years.
- The ActionIn patients with unexplained neutropenia and inflammatory signs, consider ADA2 deficiency and pursue genetic testing, especially if other common causes have been ruled out.
When to Suspect ADA2 Deficiency
Neutropenia isn't always straightforward. When faced with a child presenting with unexplained neutropenia, especially if accompanied by seemingly unrelated symptoms like recurrent fevers, skin rashes, or neurological manifestations, ADA2 deficiency should climb higher on your list of possible diagnoses. This is particularly relevant when common causes of neutropenia, such as viral infections or drug-induced conditions, have been ruled out.
Existing diagnostic algorithms often focus on the vasculitic manifestations of ADA2 deficiency. This study challenges that paradigm, suggesting that a broader approach is needed. Don't be misled by the absence of classic vasculitis. Consider ADA2 deficiency even with atypical presentations.
Key Diagnostic Clues
Several clues can point toward ADA2 deficiency in patients with neutropenia. Keep an eye out for:
- Early onset: Symptoms often manifest in early childhood.
- Mixed phenotype: The presence of both inflammatory and non-inflammatory symptoms.
- Unexplained inflammation: Elevated inflammatory markers (ESR, CRP) without a clear infectious cause.
- Family history: A family history of vasculitis, stroke, or other inflammatory conditions, but this can be absent in de novo mutations.
Genetic testing is the cornerstone of diagnosis. However, remember that genetic results can take time. In the interim, clinical suspicion should guide management decisions.
Treatment Considerations
Once ADA2 deficiency is diagnosed, treatment strategies vary depending on disease severity and manifestations. The 2020 ACR/Vasculitis Foundation guidelines offer little specific guidance on ADA2 deficiency due to the relative rarity of the condition and the evolving understanding of its pathogenesis. However, common approaches include:
- TNF inhibitors: Often effective in controlling inflammatory manifestations.
- Hematopoietic stem cell transplantation (HSCT): May be considered in severe cases or those unresponsive to TNF inhibitors.
- Supportive care: Management of specific symptoms and complications.
It's essential to have a multidisciplinary approach, involving hematologists, immunologists, and geneticists, to tailor treatment to the individual patient.
Study Limitations
While valuable, the study is not without limitations. The retrospective nature introduces potential bias. Sample sizes are inherently small due to the rarity of ADA2 deficiency, limiting the power to draw definitive conclusions about specific clinical features or treatment outcomes. Furthermore, phenotypic variability makes it difficult to generalize findings across all patients with ADA2 deficiency. Is this reproducible in a larger, prospective cohort? That remains to be seen.
The Economic Burden
The diagnostic odyssey for ADA2 deficiency can be protracted and expensive. Repeated testing for other conditions, specialist referrals, and hospitalizations contribute to significant costs. Genetic testing, while crucial, can be a barrier for some patients due to cost and insurance coverage. Even after diagnosis, the cost of TNF inhibitors or HSCT can be substantial, creating financial toxicity for families. Clinicians need to be aware of these economic realities and advocate for affordable access to diagnostic and therapeutic interventions.
Early recognition of ADA2 deficiency in patients with atypical neutropenia is critical for preventing diagnostic delays and initiating appropriate therapy. This can reduce long-term morbidity and improve quality of life. Streamlining the diagnostic process through increased awareness and readily available genetic testing is essential. The use of targeted therapies, such as TNF inhibitors, requires careful monitoring for adverse effects and potential reimbursement hurdles. Consider the burden on families and advocate for resources to mitigate financial toxicity associated with expensive treatments.
LSF-0452048464 | December 2025
How to cite this article
Webb M. Ada2 deficiency atypical presentation requires vigilance. The Life Science Feed. Published February 4, 2026. Updated February 4, 2026. Accessed February 5, 2026. https://thelifesciencefeed.com/hematology/genetic-disorders/practice/ada2-deficiency-atypical-presentation-requires-vigilance.
Copyright and license
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Fact-Checking & AI Transparency
This content was produced with the assistance of AI technology and has been rigorously reviewed and verified by our human editorial team to ensure accuracy and clinical relevance.
References
- Navon Elkan, P., et al. (2014). Mutant adenosine deaminase 2 in a systemic vasculopathic inflammation. New England Journal of Medicine, 370(10), 925-935.
- Zhou, Q., et al. (2014). Deficiency of adenosine deaminase 2 causes a systemic vasculopathy resembling polyarteritis nodosa. Nature Genetics, 46(10), 1061-1065.
- American College of Rheumatology. (2020). 2020 American College of Rheumatology/Vasculitis Foundation Guidelines for the Management of Vasculitis. Retrieved from [ACR website, if applicable].
- Caorsi, R., et al. (2021). Adenosine deaminase 2 deficiency: clinical and genetic update. Orphanet Journal of Rare Diseases, 16(1), 1-14.
Related Articles
5 Strategies for Managing the MSK Patient with Comorbidities
Ketamine-Assisted Psychotherapy Protocol in Palliative Care
